A study led by the University of Edinburgh has identified a distinct androgen signature in the blood of women with endometriosis, correctly classifying more than 95% of the 159 patients tested against 57 controls. The finding, published in the European Journal of Endocrinology, isolates elevated levels of 11-oxygenated androgens—particularly 11-ketotestosterone—as a hormonal fingerprint that challenges the long-held view of the condition as solely oestrogen-driven. Because diagnosis in the UK currently averages nine years and requires laparoscopic surgery, researchers and the charity Endometriosis UK describe a non-invasive blood test as a long-awaited tool that could compress the diagnostic window to months, though larger trials are still needed to validate the signature.

Viewed alongside a separate Danish nationwide cohort study of roughly three million women, the hormonal picture becomes more complex. That analysis, published in the Journal of the American Medical Association, found that use of certain progestogen-only contraceptives—particularly injectable medroxyprogesterone—was associated with a fourfold higher risk of meningioma, a typically benign brain tumour. Clinicians in Toronto and London stress that the absolute risk remains extremely rare, affecting about one in ten thousand people, and that the elevated risk recedes within years of discontinuation. The Society of Obstetricians and Gynaecologists of Canada frames the risk as acceptable for most women given the benefits in managing endometriosis, heavy bleeding, and cancer risk reduction, but the data add urgency to individualised risk-benefit conversations.

In parallel, clinicians in Brazil are drawing attention to the perimenopause as a window of opportunity that can open up to a decade before menstruation stops. Dr Joaquim Menezes, a longevity specialist, notes that fluctuating oestrogen and progesterone levels during this transition affect sleep, cognition, metabolism, and bone integrity, yet symptoms are frequently misattributed to stress or ageing. Endocrinologist Luana Concha adds that the same hormonal shifts influence neurotransmitters such as serotonin, making anxiety and irritability biologically grounded rather than a matter of willpower. Both argue that early identification allows tissues with still-responsive hormone receptors to benefit more from lifestyle and, where appropriate, pharmacological interventions, preserving cardiovascular and skeletal health.

These condition-specific insights sit within a broader preventive push. US health authorities, including the CDC and the American Heart Association, now recommend cholesterol screening from age 19 or 20, noting that Gen Z lifestyles—high in ultra-processed foods and sedentary patterns—can silently elevate lipid levels years before symptoms appear. Meanwhile, exercise scientists in North America are refining strength-training guidance: the American College of Sports Medicine’s latest position stand, based on 137 reviews, confirms that moderate loads taken close to muscular failure build muscle and bone as effectively as heavy weights, while grip strength, measured by a simple dead hang, remains a reliable correlate of overall mortality risk. The next milestone to watch is the search for industry partners to develop the Edinburgh team’s diagnostic blood test, which will determine whether a hormonal signature can move from a 95% classification rate in a research cohort to a clinically deployed screening tool.